Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00589212 · ClinicalTrials.gov registry record · Phase 2
GliaSite 1-3 Mets Study
A Phase 2 study of Brain Metastases, sponsored by Hologic.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00589212 is a Phase 2 study of Brain Metastases that has completed, run by Hologic. The registered enrollment target is 50 participants, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00589212, a Phase 2 study of Brain Metastases, has completed, sponsored by Hologic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study has been designed to compile information on the efficacy of the GliaSite RTS combined with radiosurgery in the treatment of newly diagnosed metastatic brain tumors.
Conditions Studied
Interventions
- DEVICE GliaSite Radiation Therapy System
Study Locations (1)
Tennessee
- Methodist University Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2003-10 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00589212
The ClinicalTrials.gov registry entry for NCT00589212 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (76% lower). The listed sponsor is Hologic, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 1 intervention - of which GliaSite Radiation Therapy System is the first listed.
NCT00589212 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT00589212 about?
NCT00589212 is a clinical study titled "GliaSite 1-3 Mets Study". This study has been designed to compile information on the efficacy of the GliaSite RTS combined with radiosurgery in the treatment of newly diagnosed metastatic brain tumors.
What is the current status of trial NCT00589212?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2003-10. Estimated completion is 2008-03.
What conditions does trial NCT00589212 study?
This clinical trial studies the following conditions: Brain Metastases.
What interventions are being tested in trial NCT00589212?
The interventions under investigation include: GliaSite Radiation Therapy System (DEVICE).
Who is sponsoring clinical trial NCT00589212?
This trial is sponsored by Hologic, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00589212 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
RECRUITING · Phase 2
-
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
RECRUITING · Phase 2
-
Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
RECRUITING · Phase 2
-
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
RECRUITING · Phase 2
-
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
RECRUITING · Phase 2
-
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.